Table 2. Recommended targets for clinically meaningful trials in NSCLC [modified after (20)].
NSCLC histology | OS (base line, months) | Primary endpoint: improvement of OS | Secondary endpoint: 1-year-survival | Secondary endpoint: improvement of PFS |
---|---|---|---|---|
Squamous | 10–11 | 2.5–3 months (HR =0.77–0.80) | 44–53% | 4 months |
Non-squamous | 14 | 3.25–4 months (HR =0.76–0.80) | 53–61% | 3 months |
NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; HR, hazard ratio.